Companies in #Type 2 diabetes (including insulin-deficient)
Found 1 company operating in this sector.
Biomea Fusion (NASDAQ: BMEA) is a clinical-stage diabetes and obesity medicines company developing oral covalent small-molecule drugs, led by icovamenib (BMF-219), a covalent menin inhibitor. The COVALENT program spans Phase 2 trials in type 1 and type 2 diabetes; on August 24, 2026 the company announced completion of enrollment in COVALENT-211 (icovamenib in insulin-deficient type 2 diabetes), and on August 13, 2026 it announced first-patient-dosed in the OPAL study evaluating icovamenib in combination with semaglutide in obesity. The pipeline also includes BMF-650, a Phase 1 GLP-131 candidate for obesity. Incorporated in 2017 and headquartered in San Carlos, California, Biomea Fusion listed on Nasdaq in April 2021.